2026 ISGD Clinical Trials Summit

UNITING VISION, SCIENCE, AND PARTNERSHIP TO ACCELERATE KIDNEY CURES

The 2026 ISGD Clinical Trials Innovation Summit will serve as a global hub for clinical trialists, nephrologists, and other stakeholders committed to transforming the future of kidney disease research. Convening world-renowned keynote speakers and innovative collaborative formats, the Summit is designed to accelerate innovation, catalyze collaboration, and design solutions to the key challenges of clinical trials in glomerular diseases and beyond.

This inaugural Clinical Trials Innovation Summit will spotlight the most pressing challenges in clinical trial design, patient stratification, new drug target identification, and regulatory endpoints. Featuring a thoughtfully curated program with panel discussions, speed networking, and interactive workshops, attendees will benefit from practical training sessions, robust participation opportunities for emerging investigators, and focused cross-stakeholder breakout groups. The Summit organizers aim to produce not only a meaningful and informative experience, but a roadmap for improved clinical trials to be published as a product of the meeting. The conference design emphasizes inclusivity, balancing academic, industry, regulatory, and patient advocacy perspectives to ensure actionable solutions for diverse and global kidney patient populations.

ABOUT THE ORGANIZERS

Hosted by the International Society of Glomerular Disease (ISGD) in partnership with the renowned nephrology and clinical trials leadership team of the University of Texas Medical Branch, the Clinical Trials Innovation Summit delivers an expertly curated platform that fuses scientific rigor, operational excellence, and hands-on engagement for attendees.

ISGD’s recent stewardship of the acclaimed 15^th International Podocyte Conference, praised by faculty and attendees for its seamless integration of basic, translational, and clinical content as well as unparalleled community building, is a direct template for the Clinical Trials Innovation Summit. The Podocyte Conference’s sold-out attendance, sophisticated logistics, and highly rated science underscore ISGD’s ability to convene world leaders, innovate session formats, and maximize value for all participants.

ISGD

TOUCH

ISGD PRESIDENT Tobias B. Huber, MD

ISGD PRESIDENTTobias B. Huber, MD

President, ISGD

Chair, Center of Internal Medicine; Director, Third Department of Medicine (Nephrology, Rheumatology, Endocrinology); Director, Hamburg Center for Kidney Health, UKE Hamburg